Texas Roadhouse earnings missed by $0.05, revenue topped estimates
In a recent transaction, Bryan K. Gathagan, a director at Immucell Corp (NASDAQ:ICCC), purchased 1,000 shares of the company’s common stock. The shares were acquired on June 12, 2025, at a price of $6.32 per share, amounting to a total investment of $6,320. Following this transaction, Gathagan holds a total of 1,000 shares in the company. Immucell Corp, based in Portland, Maine, is known for its work in animal health products.The insider purchase comes as the company shows strong momentum, with the stock up over 35% in the past six months. According to InvestingPro analysis, Immucell’s revenue grew 28% in the last twelve months to $27.3 million, though the company remains unprofitable. The company maintains a healthy balance sheet with a current ratio of 4.12, indicating strong liquidity. Based on InvestingPro’s Fair Value model, the stock appears slightly overvalued at current levels. For deeper insights into ICCC’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, ImmuCell Corporation reported its financial results for the first quarter of 2025, showcasing a strong performance with product sales reaching a record $8.1 million, marking an 11% increase from the previous year. The company’s earnings per share stood at $0.16, and it improved its gross margin to 42% from 37% in the previous quarter. Additionally, ImmuCell introduced a new bulk powder product format for its First Defense line, which is expected to further enhance sales. The company is targeting an annual production capacity of $40 million and is exploring strategic options for new product lines. Analysts have noted ImmuCell’s robust financial performance, with adjusted EBITDA rising to $2.3 million from $705,000 in the same quarter of the previous year. The company has also been cautious about making specific revenue projections but remains optimistic about its investigational use of the Repayne product. These developments reflect ImmuCell’s strategic focus on expanding its product line and enhancing production capacity, contributing to its growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.